Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Advair

    Jump to

    • Cipla: M&A positioning, new US regime are key wild cards

      The management is primarily focusing on Indian assets which can bring synergy, followed by US assets. Cipla’s continued investment in US subsidiary InvaGen would de-risk the business model from a compliance point of view.

    • US FDA plant observations at Cipla cause 6-month delay in product launches: CEO

      The biggest product under manufacture in the Pithampur facility is Advair which has a market size of $700 million

    • Cipla: Sailing well on the US pharma business front

      The company’s chronic portfolio continues to gain strength and the US base business has moved to a new orbit. This is supportive for medium-term earnings growth, which makes us constructive on the business.

    • Cipla: Sharp improvement in margins not likely to sustain

    • Cipla: Watch out for respiratory and Peptide pipelines

    • Cipla: Targets for US complex generics on track

    • Cipla: Focus shifts to FY23 launches

    • Cipla: M&A opportunity could be near-term trigger

    • Cipla — Large part of COVID opportunity has played out

    • Prospects for US business and leadership in respiratory therapies make Cipla attractive

    • Cipla: Respiratory pipeline adds oxygen, accumulate

    • When Rakesh Jhunjhunwala grilled Lupin top brass after muted Q4 results

    • Cipla down 2% on Nomura downgrade, valuations expensive

    • How generic asthma drug could 'change the face of Cipla'

    • Inhaler launch in EU to add $55mn to Cipla FY15 rev: Nomura

    • Cipla at new high, up 8%; respiratory drug launch in UK key

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347